Apellis Pharmaceuticals, a biotech firm developing therapies that control the body’s immune system, has secured a $47.1M Series d funding round. The capital will fuel its mission to create transformative treatments for a broad range of debilitating diseases by specifically targeting C3, a central component of the complement cascade.
This strategic focus on C3 is designed to address all three pathways that can drive disease, offering a platform with potential applications across ophthalmology, nephrology, hematology, and neurology, where patients often have limited treatment options.
